Avatar image

Vésale Bioscience (Inteliphage)

Company  |
Belgium, Mont-Saint-Guibert

Primary tabs

About your organization / profile

Vésale is the leader in personalized phage therapy, providing a safe and efficacious solution to the second largest cause of death globally: Difficult-to-Treat Infections ("DTI").  13.7 million infection-related deaths in 2019, of which 4.2 million deaths (30.9%) associated with the top 5 bacterial pathogens (both resistant and susceptible to antibiotics).

Vésale has developed the Phagogram, a unique susceptibility test which makes a scalable and profitable personalized treatment possible and efficacious, thanks to its unique features: it is fast, automated, on-site and easy-to-use, without the need for human interpretation of results. With its large and ever-growing phage library, and its GMP production unit, Vésale is already able to successfully treat a very significant portion of the 250,000 last-hope patients (EU5 + BeNeLux only) with infections caused by the 4 ESKP bacteria (S.a, P.a, K.p, E.c).

Why invest in phage therapy now? Because the regulatory pathway for personalized phage therapy is now clear and confirmed by regulatory authorities for last-hope patients in Europe without any need for clinical trials, and because the new draft European regulation is providing a favorable marketing authorization pathway designed to promote personalized phage therapy, fully aligned with our business model and clinical strategy.

Network (0)

There are no organizations in the network.

Recent activities

Avatar

Vésale Bioscience (Inteliphage) is now a member of the EIC ACCESS+ community.

Avatar

Vésale Bioscience (Inteliphage) has taken its fundraising offline. 

Avatar

The pitchdeck document has been updated in the dataroom.

Avatar

Vésale Bioscience (Inteliphage) has published fundraising documents

Avatar

Guillaume de Viron has joined Vésale Bioscience (Inteliphage)